← Leaderboards
David Chimento
Rockland Immunochemicals, Inc.
$1,448,493
Attributed
$1,448,493
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2011–16$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$1,448,493 · 3
By mechanism
N44$999,002 · 1
N43$449,491 · 2
Top collaborators
No co-investigators on record.
Most similar at Rockland Immunochemicals, Inc.
Same institution · by research overlap
- Hiep T Tran$7,949,125
- Carl A Ascoli$249,975
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsProductionAntibodiesBaseImmunoassayTumorResearch PersonnelValidationPharmacodynamicsPharmaceutical PreparationsRecombinant ProteinsAntineoplastic AgentsSamplingSmall Business Innovation Research GrantPropertyEnzyme-Linked Immunosorbent AssayCancer TherapyCellsMutantPathway InteractionsProtocols DocumentationPhosphorylationReagentXenograft Procedure
Grant awards (3)
IGF::OT::IGF SYSTEMIC PRE-TARGETED RADIOIMMUNOTHERAPY WITH BISPECIFIC NANOBODIES FOR CANCER TREATMENT$299,625
N43 · FY2016 · CA · contact PI
SBIR TOPIC 229, PHASE II: PHARMACODYNAMIC ASSAY FOR AKT FOR USE WITH PI3K/AKT/MT$999,002
N44 · FY2011 · CA · contact PI
TAS::75 0849::TAS SBIR TOPIC 292 PHASE I DEVELOPMENT OF MOLECULAR PHARMACODYNAMI$149,866
N43 · FY2011 · CA · contact PI